|
US10426740B1
(en)
|
2010-08-18 |
2019-10-01 |
Avm Biotechnology, Llc |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
|
EP2753351B1
(en)
|
2011-09-08 |
2017-06-21 |
Yeda Research and Development Co. Ltd. |
Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
|
|
US20150320799A1
(en)
|
2012-12-20 |
2015-11-12 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
SG10202104804PA
(en)
|
2014-10-20 |
2021-06-29 |
Juno Therapeutics Inc |
Methods and compositions for dosing in adoptive cell therapy
|
|
BR112017025166A2
(en)
*
|
2015-05-28 |
2018-07-31 |
Kite Pharma, Inc. |
Methods of Conditioning Patients for T-Cell Therapy
|
|
KR20230148387A
(ko)
*
|
2015-05-28 |
2023-10-24 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위한 진단 방법
|
|
US11179448B2
(en)
|
2015-07-16 |
2021-11-23 |
Yeda Research And Development Co. Ltd. |
Genetically modified anti-third party central memory T cells and use of same in immunotherapy
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
PL3436079T3
(pl)
|
2016-04-01 |
2021-12-20 |
Kite Pharma, Inc. |
Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
SG11201808751SA
(en)
|
2016-04-08 |
2018-11-29 |
Adaptimmune Ltd |
T cell receptors
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
CA3023820A1
(en)
|
2016-05-25 |
2017-11-30 |
The Council Of The Queensland Institute Of Medical Research |
Methods of immunotherapy
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
JP6971319B2
(ja)
|
2016-12-28 |
2021-11-24 |
グリーン・クロス・ラブ・セル・コーポレイション |
キメラ抗原受容体及びそれを発現するナチュラルキラー細胞
|
|
IL268126B2
(en)
*
|
2017-01-18 |
2024-02-01 |
Yeda Res & Dev |
Genetically engineered Veto cells and their uses in immunotherapy
|
|
KR20250067948A
(ko)
*
|
2017-01-20 |
2025-05-15 |
아타라 바이오테라퓨틱스 인크. |
자가 t 세포를 사용하여 다발성 경화증을 치료하는 방법
|
|
EP3579870A4
(en)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
|
|
CA3053539A1
(en)
|
2017-02-27 |
2018-08-30 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
ES2954311T3
(es)
|
2017-04-01 |
2023-11-21 |
Avm Biotechnology Llc |
Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular
|
|
CN110494158A
(zh)
|
2017-04-03 |
2019-11-22 |
凯德药业股份有限公司 |
使用包含优化的多功能t细胞的嵌合受体t细胞进行治疗
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
CN110753555A
(zh)
|
2017-04-19 |
2020-02-04 |
得克萨斯州大学系统董事会 |
表达工程化抗原受体的免疫细胞
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
KR20210118479A
(ko)
|
2017-05-26 |
2021-09-30 |
카이트 파마 인코포레이티드 |
배아 중간엽 전구 세포를 제조하고 사용하는 방법
|
|
KR20200054160A
(ko)
|
2017-06-02 |
2020-05-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
|
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
JP7654240B2
(ja)
|
2017-09-19 |
2025-04-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
|
|
JP7239567B2
(ja)
|
2017-10-02 |
2023-03-14 |
ガミダ セル リミテッド |
Ｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
EP3703710B9
(en)
*
|
2017-10-31 |
2024-12-04 |
Allogene Therapeutics, Inc. |
Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells for treating refractory and/or relapsed large b-cell lymphoma or refractory and/or relapsed follicular lymphoma
|
|
WO2019089855A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for generating therapeutic compositions of engineered cells
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
CN111565730B
(zh)
|
2017-11-09 |
2024-09-17 |
桑格摩生物治疗股份有限公司 |
细胞因子诱导型含sh2蛋白（cish）基因的遗传修饰
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
EP3712178A4
(en)
|
2017-11-14 |
2021-08-11 |
Green Cross Lab Cell Corporation |
ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
US11390655B2
(en)
|
2017-11-16 |
2022-07-19 |
Kite Pharma, Inc. |
Modified chimeric antigen receptors and methods of use
|
|
US12161670B2
(en)
|
2017-12-08 |
2024-12-10 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
EP3740285A1
(en)
|
2018-01-15 |
2020-11-25 |
Pfizer Inc. |
Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist
|
|
AU2019209432A1
(en)
|
2018-01-22 |
2020-08-06 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for CAR T cells
|
|
CN111936518A
(zh)
|
2018-02-06 |
2020-11-13 |
西雅图儿童医院（Dba西雅图儿童研究所） |
对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
|
|
EP3755349A4
(en)
|
2018-02-21 |
2021-11-17 |
Board of Regents, The University of Texas System |
PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
|
|
WO2019165237A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
CN111989344A
(zh)
*
|
2018-03-09 |
2020-11-24 |
科济生物医药（上海）有限公司 |
用于治疗肿瘤的方法和组合物
|
|
BR112020018658A2
(pt)
|
2018-03-15 |
2020-12-29 |
KSQ Therapeutics, Inc. |
Composições de regulação gênica e métodos para imu-noterapia aprimorada
|
|
CA3084179A1
(en)
|
2018-03-22 |
2019-09-26 |
Windmil Therapeutics, Inc. |
Prostate cancer specific marrow infiltrating lymphocytes and uses thereof
|
|
WO2019191752A1
(en)
*
|
2018-03-30 |
2019-10-03 |
Ohio State Innovation Foundation |
Methods for pre-conditioning patients for t-cell therapy
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
JP7584299B2
(ja)
|
2018-05-23 |
2024-11-15 |
ナショナル ユニバーシティ オブ シンガポール |
Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現
|
|
EP3801572B1
(en)
|
2018-06-01 |
2024-07-03 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
EP3810780A1
(en)
|
2018-06-22 |
2021-04-28 |
Kite Pharma Eu B.V. |
Compositions and methods for making engineered t cells
|
|
AU2019310430A1
(en)
*
|
2018-07-23 |
2021-02-25 |
Magenta Therapeutics, Inc. |
Use of an anti-CD2 antibody drug conjugate (ADC) in allogeneic cell therapy
|
|
JP2021532116A
(ja)
*
|
2018-07-23 |
2021-11-25 |
マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. |
同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
|
|
AU2019346335B2
(en)
|
2018-09-28 |
2024-07-25 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
EP3632446B3
(en)
|
2018-10-03 |
2024-01-24 |
AVM Biotechnology, LLC |
Immunoablative therapies
|
|
EP3488851A1
(en)
|
2018-10-03 |
2019-05-29 |
AVM Biotechnology, LLC |
Immunoablative therapies
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
AU2019372331A1
(en)
*
|
2018-11-01 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
JP2022518150A
(ja)
*
|
2019-01-07 |
2022-03-14 |
マジェンタ セラピューティクス インコーポレイテッド |
細胞療法での抗ｃｄ４５抗体－薬物結合体（ａｄｃ）の使用経験
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
SG11202110261QA
(en)
*
|
2019-03-21 |
2021-10-28 |
Gamida Cell Ltd |
Expanded nk cell fractions for transplantation in combination therapy
|
|
TW202042824A
(zh)
|
2019-03-27 |
2020-12-01 |
賓夕法尼亞大學董事會 |
Tn-MUC1嵌合抗原受體（CAR）T細胞療法
|
|
KR20210152515A
(ko)
|
2019-04-12 |
2021-12-15 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스 및 아이올로스의 트리시클릭 분해제
|
|
TW202108150A
(zh)
|
2019-05-03 |
2021-03-01 |
美商凱特製藥公司 |
投與嵌合抗原受體免疫療法之方法
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
PE20220231A1
(es)
|
2019-06-25 |
2022-02-07 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
AU2020307667A1
(en)
|
2019-06-27 |
2022-01-20 |
Crispr Therapeutics Ag |
Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
IL292665B1
(en)
*
|
2019-11-06 |
2025-10-01 |
Kite Pharma Inc |
Chimeric antigen receptor T cell therapy
|
|
CN112079934B
(zh)
*
|
2019-12-17 |
2021-01-29 |
合源生物科技(天津)有限公司 |
一种靶向cd19的嵌合抗原受体及其用途
|
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
MX2022009041A
(es)
*
|
2020-01-24 |
2022-10-07 |
Juno Therapeutics Inc |
Metodos de dosificacion y tratamiento de linfoma folicular y linfoma de zona marginal en terapia celular adoptiva.
|
|
WO2021191871A1
(en)
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
WO2021191870A1
(en)
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
EP4171617A1
(en)
|
2020-06-30 |
2023-05-03 |
Mendus B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
WO2022093925A1
(en)
|
2020-10-28 |
2022-05-05 |
Kite Pharma, Inc. |
Flow cytometric method for characterization of t-cell impurities
|
|
EP4240405A1
(en)
|
2020-11-05 |
2023-09-13 |
Mendus B.V. |
Use of tumor-independent antigens in immunotherapies
|
|
CA3207182A1
(en)
|
2021-01-10 |
2022-07-14 |
Kite Pharma, Inc. |
T cell therapy
|
|
CA3203705A1
(en)
|
2021-01-22 |
2022-07-28 |
Erik Hans MANTING |
Methods of tumor vaccination
|
|
JP2024507199A
(ja)
|
2021-02-20 |
2024-02-16 |
カイト ファーマ インコーポレイテッド |
免疫療法を選択するための遺伝子マーカー
|
|
AU2022227686A1
(en)
|
2021-02-25 |
2023-07-27 |
Lyell Immunopharma, Inc. |
Ror1 targeting chimeric antigen receptor
|
|
US12357646B2
(en)
*
|
2021-05-14 |
2025-07-15 |
Kite Pharma, Inc. |
Chimeric antigen receptor T cell therapy
|
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
|
CA3232968A1
(en)
|
2021-10-14 |
2023-04-20 |
Jasper Williams |
Immune cells having co-expressed shrnas and logic gate systems
|
|
US20250041339A1
(en)
|
2021-11-19 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell Therapy
|
|
AU2023221839A1
(en)
|
2022-02-15 |
2024-08-22 |
Kite Pharma, Inc. |
Predicting adverse events from immunotherapy.
|
|
US20240002800A1
(en)
|
2022-05-16 |
2024-01-04 |
Mendus B.V. |
Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
|
|
TW202530421A
(zh)
|
2022-10-28 |
2025-08-01 |
美商凱特製藥公司 |
用於將免疫療法最佳化之因素
|
|
CN119997962A
(zh)
|
2022-10-28 |
2025-05-13 |
凯德药业股份有限公司 |
改善免疫疗法的功效和持久应答
|
|
EP4619010A2
(en)
*
|
2022-11-16 |
2025-09-24 |
Nkarta, Inc. |
Dosing regimens for combination therapies
|
|
DE102022132084B4
(de)
|
2022-12-02 |
2024-08-22 |
Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) |
Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
|
|
DE102022132083B4
(de)
|
2022-12-02 |
2024-08-22 |
Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) |
Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
|
|
DE102022132082B4
(de)
|
2022-12-02 |
2024-08-08 |
Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) |
Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
TW202442689A
(zh)
|
2023-03-03 |
2024-11-01 |
美商亞森諾生物科學公司 |
靶向ｐｓｍａ及ｃａ９之系統
|
|
US20240309428A1
(en)
|
2023-03-17 |
2024-09-19 |
Kite Pharma, Inc. |
Impact of tumor microenvironment on efficacy of immunotherapy
|
|
WO2024211852A1
(en)
*
|
2023-04-07 |
2024-10-10 |
Fate Therapeutics, Inc. |
Ipsc-derived nk cell for lymphoma treatment
|
|
WO2024243428A2
(en)
*
|
2023-05-24 |
2024-11-28 |
Instil Bio Inc. |
Use of fusion constructs for cell therapy
|
|
WO2025006561A2
(en)
*
|
2023-06-27 |
2025-01-02 |
Nkarta, Inc. |
Methods for treatment using cd19-directed immunotherapies
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025096419A1
(en)
|
2023-10-31 |
2025-05-08 |
Lyell Immunopharma, Inc. |
T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof
|
|
WO2025096517A1
(en)
|
2023-11-01 |
2025-05-08 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy efficacy
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
US20250290154A1
(en)
|
2024-03-04 |
2025-09-18 |
Kite Pharma, Inc. |
Predictive markers for immunotherapy
|